Clinical Trial

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This study is designed to collect real-world data on the safety and performance of the Endogenex System in the cohort of participants who were originally randomized to the sham control arm of the ReCET Study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-26.
Status change: Not Yet Recruiting → Enrolling by Invitation 2026-06-29
Trial Details
NCT Number NCT07197788
Lead Sponsor Endogenex, Inc.
Conditions Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes, Diabetes
Enrollment 50 participants
Start Date 2026-09
Primary Completion 2027-10 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-04